PDS Biotech prices up to USD 22.55 million PIPE led by Nant Capital
Reuters2026/09/08 12:34- PDS Biotech announced a PIPE financing of up to USD 22.55 million led by Nant Capital, with additional participation from existing investors.
- Initial closing targets about USD 11.55 million around Sept. 11, 2026, via unregistered common stock or pre-funded warrants with common warrants.
- Units priced at USD 0.28 per share unit or USD 0.28 per pre-funded unit.
- Milestone closing would add USD 11 million if a registrational Phase 3 PDS0301 protocol is submitted to the FDA in collaboration with Nant.
- Nant can appoint two directors if it owns at least 15%, including Patrick Soon-Shiong; proceeds earmarked for debt repayment, R&D, working capital.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
"I am now the market maker, if you want to bet against me, go ahead" Besant warns the market not to short the yen against him
Bessent stated, "When we intervene in the yen, I know exactly what the Japanese, the Bank of Japan, and Japanese policymakers are going to do." With fundamental support from the Bank of Japan's expected 25 basis point rate hike this month, short-sellers will face the dual pressure of policy intervention and an interest rate shift. Analysts believe that Bessent's tough rhetoric serves both as psychological pressure and as an indication that further actions are being prepared.
South Korean stocks extend gains to over 1%
Flexsteel director William S. Creekmuir sells 3,100 common shares worth $252,891.8
Cerebras CEO Andrew D. Feldman reports sale of USD 7.96 million Class A shares
Crypto prices
More
